Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Expenditures: 2010-2021

Historic Capital Expenditures for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2021 value amounting to $8.9 million.

  • Neurocrine Biosciences' Capital Expenditures rose 97.78% to $8.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $23.4 million, marking a year-over-year increase of 114.68%. This contributed to the annual value of $38.2 million for FY2024, which is 34.98% up from last year.
  • According to the latest figures from Q4 2021, Neurocrine Biosciences' Capital Expenditures is $8.9 million, which was up 56.14% from $5.7 million recorded in Q3 2021.
  • Over the past 5 years, Neurocrine Biosciences' Capital Expenditures peaked at $12.4 million during Q3 2018, and registered a low of $397,000 during Q2 2017.
  • Over the past 3 years, Neurocrine Biosciences' median Capital Expenditures value was $4.4 million (recorded in 2019), while the average stood at $4.1 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 88.57% in 2020, then soared by 1,325.00% in 2021.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Capital Expenditures stood at $2.4 million in 2017, then spiked by 152.33% to $6.0 million in 2018, then tumbled by 53.32% to $2.8 million in 2019, then skyrocketed by 60.71% to $4.5 million in 2020, then soared by 97.78% to $8.9 million in 2021.
  • Its last three reported values are $8.9 million in Q4 2021, $5.7 million for Q3 2021, and $4.3 million during Q2 2021.